Dipexium hits 50% enrollment in second Phase 3 trial

Dipexium Pharmaceuticals

Dipexium Pharmaceuticals’ (NASDAQ: DPRX) OneStep-2 pivotal Phase 3 clinical trial has reached the 50% enrollment milestone.

OneStep-1 and OneStep-2 are identical, pivotal Phase 3 clinical trials, with 180 patients in each study, being conducted under a Special Protocol Assessment with the FDA for evaluation of Locilex for the treatment of patients with mild infections of diabetic foot ulcers.

Currently, OneStep-1 and OneStep-2 are approximately 56% and 50% enrolled, respectively. A total of 62 clinical trial centers are open for enrollment across both pivotal Phase 3 clinical studies.

The company is targeting a NDA submission in the second half of 2016.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.